{"title":"Comment on: Get OUT: Factors Associated With a Longer Length of Stay in Patients Admitted With an Acute Gout Flare, and the Effects of Anakinra on Length of Stay","authors":"Selin Cilli Hayıroğlu","doi":"10.1111/1756-185x.70556","DOIUrl":"10.1111/1756-185x.70556","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146029452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bucillamine is a conventional synthetic disease-modifying antirheumatic drug that can be used as a methotrexate alternative. However, which patients with rheumatoid arthritis can benefit from bucillamine treatment has not been established.
Methods
Patients who had taken bucillamine and discontinued it in 2021 due to a nationwide supply shortage were included in this study. We followed up these patients regarding arthritis exacerbation after bucillamine discontinuation until March 2025. Baseline clinical patient characteristics were compared between the exacerbation and non-exacerbation groups.
Results
Thirteen of the 18 patients experienced arthritis exacerbation, whereas five remained exacerbation-free for up to 48 months. The baseline rheumatoid factor levels were significantly higher in the exacerbation group (49 U/mL) than in the non-exacerbation group (6 U/mL). Receiver operating characteristic and Kaplan–Meier analyses showed that baseline RF levels ≥ 28 U/mL predicted arthritis exacerbation after bucillamine discontinuation (sensitivity 76.2% and specificity 80.0%).
Conclusion
Following bucillamine discontinuation, arthritis exacerbations occurred more frequently in patients with rheumatoid factor levels of 28 U/mL or higher, alongside an increase in these levels. Rheumatoid factor levels may serve as a useful biomarker for identifying patients who would benefit from continued bucillamine therapy.
{"title":"Rheumatoid Factor Levels Are Associated With Arthritis Exacerbation After Bucillamine Discontinuation","authors":"Yusuke Ogata, Masumi Bamba, Koichi Bamba, Ryo Hisada, Hiroyuki Nakamura","doi":"10.1111/1756-185x.70551","DOIUrl":"10.1111/1756-185x.70551","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Bucillamine is a conventional synthetic disease-modifying antirheumatic drug that can be used as a methotrexate alternative. However, which patients with rheumatoid arthritis can benefit from bucillamine treatment has not been established.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients who had taken bucillamine and discontinued it in 2021 due to a nationwide supply shortage were included in this study. We followed up these patients regarding arthritis exacerbation after bucillamine discontinuation until March 2025. Baseline clinical patient characteristics were compared between the exacerbation and non-exacerbation groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirteen of the 18 patients experienced arthritis exacerbation, whereas five remained exacerbation-free for up to 48 months. The baseline rheumatoid factor levels were significantly higher in the exacerbation group (49 U/mL) than in the non-exacerbation group (6 U/mL). Receiver operating characteristic and Kaplan–Meier analyses showed that baseline RF levels ≥ 28 U/mL predicted arthritis exacerbation after bucillamine discontinuation (sensitivity 76.2% and specificity 80.0%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Following bucillamine discontinuation, arthritis exacerbations occurred more frequently in patients with rheumatoid factor levels of 28 U/mL or higher, alongside an increase in these levels. Rheumatoid factor levels may serve as a useful biomarker for identifying patients who would benefit from continued bucillamine therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146029439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wang H. Lee Y. H. Cheng I.H. Wang S. I. Ji J. Huo A. P. Hung Y.M. 2025 Comparative Effectiveness of TNF-α and IL-6 Inhibitors on Bone Health Outcomes and Mortality in Rheumatoid Arthritis Patients: A Retrospective Cohort Study. International Journal of Rheumatic Diseases 28 6 e70204. 10.1111/1756-185X.70204.
The funding section in the above article is incorrect. The correct information is shown below.
Funding
This work was supported by funding from the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University (CSH-2024-E-001-Y2) and Zhejiang Provincial Natural Science Foundation of China (LGJ21H100001).
{"title":"Correction to “Comparative Effectiveness of TNFα and IL6 Inhibitors on Bone Health Outcomes and Mortality in Rheumatoid Arthritis Patients: A Retrospective Cohort Study”","authors":"","doi":"10.1111/1756-185x.70553","DOIUrl":"10.1111/1756-185x.70553","url":null,"abstract":"<p>Wang H. Lee Y. H. Cheng I.H. Wang S. I. Ji J. Huo A. P. Hung Y.M. 2025 Comparative Effectiveness of TNF-α and IL-6 Inhibitors on Bone Health Outcomes and Mortality in Rheumatoid Arthritis Patients: A Retrospective Cohort Study. International Journal of Rheumatic Diseases 28 6 e70204. 10.1111/1756-185X.70204.</p><p>The funding section in the above article is incorrect. The correct information is shown below.</p><p>\u0000 <b>Funding</b>\u0000 </p><p>This work was supported by funding from the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University (CSH-2024-E-001-Y2) and Zhejiang Provincial Natural Science Foundation of China (LGJ21H100001).</p><p>We apologize for this error.</p>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185x.70553","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146029482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ahmad Jasem Abdulsalam, Renu Ambardar, Sarah Y. Alkandari
{"title":"Robotic Ultrasound-Guided Musculoskeletal Injections: The Next Frontier in Precision Medicine","authors":"Ahmad Jasem Abdulsalam, Renu Ambardar, Sarah Y. Alkandari","doi":"10.1111/1756-185x.70557","DOIUrl":"10.1111/1756-185x.70557","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Recurrent Erythema and Induration of the Upper Arm in a Young Woman: What Is the Cause?","authors":"Susumu Tsunoda, Naoki Sawa","doi":"10.1111/1756-185x.70554","DOIUrl":"10.1111/1756-185x.70554","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Osteoarthritis (OA) is a degenerative joint disease driven by complex biomechanical and inflammatory mechanisms, particularly in weight-bearing joints such as the knee. This review explores the pivotal role of biomechanics in OA pathogenesis, focusing on abnormal joint loading, malalignment, and instability as key contributors to cartilage degeneration and subchondral bone remodeling. Special attention is given to the interplay between obesity and OA, highlighting how mechanical overload and adipokine-mediated inflammation synergistically accelerate disease progression. Emerging interventions—including physical therapy, gait retraining, orthotics, high tibial osteotomy (HTO), and total knee arthroplasty (TKA)—are analyzed for their biomechanical impact. Novel technologies such as wearable sensors, finite element analysis (FEA), and digital twin models are discussed as tools for real-time assessment, predictive modeling, and personalized treatment planning. The review emphasizes the need for integrated, multiscale research strategies that account for individual biomechanical profiles and systemic factors like obesity. Advancing biomechanical precision in OA management holds promise for improving early diagnosis, optimizing interventions, and informing regenerative therapies aimed at restoring joint function and delaying disease progression.
{"title":"Biomechanics and Obesity in Osteoarthritis: From Mechanism to Precision Medicine","authors":"Shangqi Guan, Yifang Mei","doi":"10.1111/1756-185x.70539","DOIUrl":"10.1111/1756-185x.70539","url":null,"abstract":"<div>\u0000 \u0000 <p>Osteoarthritis (OA) is a degenerative joint disease driven by complex biomechanical and inflammatory mechanisms, particularly in weight-bearing joints such as the knee. This review explores the pivotal role of biomechanics in OA pathogenesis, focusing on abnormal joint loading, malalignment, and instability as key contributors to cartilage degeneration and subchondral bone remodeling. Special attention is given to the interplay between obesity and OA, highlighting how mechanical overload and adipokine-mediated inflammation synergistically accelerate disease progression. Emerging interventions—including physical therapy, gait retraining, orthotics, high tibial osteotomy (HTO), and total knee arthroplasty (TKA)—are analyzed for their biomechanical impact. Novel technologies such as wearable sensors, finite element analysis (FEA), and digital twin models are discussed as tools for real-time assessment, predictive modeling, and personalized treatment planning. The review emphasizes the need for integrated, multiscale research strategies that account for individual biomechanical profiles and systemic factors like obesity. Advancing biomechanical precision in OA management holds promise for improving early diagnosis, optimizing interventions, and informing regenerative therapies aimed at restoring joint function and delaying disease progression.</p>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alberta Yik-Bun Hoi, Rachel Koelmeyer, Shereen Oon, Fiona Goldblatt, Sean O'Neill, Vera Golder, Mandana Nikpour, Eric Francis Morand, Rangi Kandane-Rathnayake
{"title":"Prevalence, Treatment Patterns, and Outcomes Among Australian SLE Patients With Inadequately Controlled Disease Activity","authors":"Alberta Yik-Bun Hoi, Rachel Koelmeyer, Shereen Oon, Fiona Goldblatt, Sean O'Neill, Vera Golder, Mandana Nikpour, Eric Francis Morand, Rangi Kandane-Rathnayake","doi":"10.1111/1756-185x.70549","DOIUrl":"10.1111/1756-185x.70549","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Haowei Chen, Qin Dang, Yongbin Shi, David J. Hunter, Xiaomeng Wang, Hao Yang, Lei Si, Vicky Duong, Mengdi Zhang, Zhiqiang Wang, Peihua Cao, Han Cen, Su'an Tang, Changhai Ding, Zhaohua Zhu, Yanqi Liu
Aim
Using data from the Global Burden of Disease (GBD) Study 2021, this study aims to estimate the comorbidity burdens of osteoarthritis (OA) at global, regional, and national levels from 1990 to 2021.
Methods
The age-standardized prevalence and years lived with disability (YLD) rate for OA and 174 other Level-3 diseases from 204 countries and territories were extracted. A modified formula was employed to determine the comorbidity burdens for the co-occurrence of OA and one of the other 174 diseases. Cluster analysis was performed to identify different patterns in the comorbidity burden.
Results
Globally, the top three comorbidity burdens for OA in 2021 were from oral disorders, headache disorders, and age-related and other hearing loss (age-standardized comorbidity YLD rates 130.80/100 000, 124.09/100 000, and 79.54/100 000, respectively). From 1990 to 2021, the age-standardized comorbidity YLD rates for diabetes mellitus exhibited the greatest increases, with percentage changes of 108.41%. In high socio-demographic index (SDI) regions, the leading comorbidity burdens for OA were from headache disorders, oral disorders, and low back pain, whereas in low SDI regions, they were oral disorders, dietary iron deficiency, and headache disorders. Six clusters were identified, including oral disorders and headache disorders in the highest comorbidity burden with a mild changing cluster, and diabetes mellitus in the high comorbidity burden with a rapid growth cluster.
Conclusions
The comorbidity burdens of OA have increased and show different patterns. These findings underscore the importance of addressing the comorbidity burdens in conjunction with tackling the OA burden.
{"title":"The Comorbidity Burdens of Osteoarthritis and 174 Diseases, 1990–2021: A Modeling Study Based on the Global Burden of Disease Study 2021","authors":"Haowei Chen, Qin Dang, Yongbin Shi, David J. Hunter, Xiaomeng Wang, Hao Yang, Lei Si, Vicky Duong, Mengdi Zhang, Zhiqiang Wang, Peihua Cao, Han Cen, Su'an Tang, Changhai Ding, Zhaohua Zhu, Yanqi Liu","doi":"10.1111/1756-185x.70548","DOIUrl":"10.1111/1756-185x.70548","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Using data from the Global Burden of Disease (GBD) Study 2021, this study aims to estimate the comorbidity burdens of osteoarthritis (OA) at global, regional, and national levels from 1990 to 2021.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The age-standardized prevalence and years lived with disability (YLD) rate for OA and 174 other Level-3 diseases from 204 countries and territories were extracted. A modified formula was employed to determine the comorbidity burdens for the co-occurrence of OA and one of the other 174 diseases. Cluster analysis was performed to identify different patterns in the comorbidity burden.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Globally, the top three comorbidity burdens for OA in 2021 were from oral disorders, headache disorders, and age-related and other hearing loss (age-standardized comorbidity YLD rates 130.80/100 000, 124.09/100 000, and 79.54/100 000, respectively). From 1990 to 2021, the age-standardized comorbidity YLD rates for diabetes mellitus exhibited the greatest increases, with percentage changes of 108.41%. In high socio-demographic index (SDI) regions, the leading comorbidity burdens for OA were from headache disorders, oral disorders, and low back pain, whereas in low SDI regions, they were oral disorders, dietary iron deficiency, and headache disorders. Six clusters were identified, including oral disorders and headache disorders in the highest comorbidity burden with a mild changing cluster, and diabetes mellitus in the high comorbidity burden with a rapid growth cluster.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The comorbidity burdens of OA have increased and show different patterns. These findings underscore the importance of addressing the comorbidity burdens in conjunction with tackling the OA burden.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146003390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号